Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Antiviral Drugs for Lassa Fever Virus

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

    SBIR Phase II 2006 Department of Health and Human Services
  2. Small Molecule Inhibitors of Smallpox Virus Replication

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smallpox. The overall goal of this smallpox antiviral pro ...

    SBIR Phase II 2006 Department of Health and Human Services
  3. Clinical Development a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: N/A

    Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a ...

    SBIR Phase II 2006 Department of Health and Human Services
  4. IDENTIFICATION OF NEW ACETYL-COA CARBOXYLASE INHIBITORS

    SBC: CROPSOLUTION, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Acetyl-CoA carboxylase (ACC) catalyzes the first step in fatty acid biosynthesis and its product, malonyl-CoA, inhibits fatty acid oxidation. These functions make ACC a prime target for the development of therapeutics to treat obesity and type 2 diabetes. Knockout studies in mice, and animal studies with ACC inhibitors, have validated this approach. The most po ...

    SBIR Phase II 2006 Department of Health and Human Services
  5. Insulating Coatings for Implant Devices and Ribbon Cables

    SBC: PREMITEC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Summary Advancements in device miniaturization, integrated circuits packaging, microfabrication technologies, and biocompatible materials have made possible the development of complex neural prostheses designed to restore lost functions such as movement, hearing or vision. Neurological diseases result in significant impairment for millions of individuals worldw ...

    SBIR Phase II 2006 Department of Health and Human Services
  6. Web Based Phenotyping With Magnetic Resonance Histology

    SBC: MRPATH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In phase I of the project we have demonstrated the feasibility of web based morphologic phenotyping of the mouse using magnetic resonance histology. We have exceeded our goal of isotropic resolution at 100 microns by 8x with isotropic resolution at 50 microns. While this spatial resolution provides extraordinary anatomic detail, it results in enormous volume ...

    SBIR Phase II 2003 Department of Health and Human Services
  7. Promotion of Wound Vascularization and Closure

    SBC: Encelle, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Progression of diabetic foot ulcers is the leading cause of lower limb amputations in the U.S. More than 800,000 foot ulcers are treated annually with progression to more than 86,000 amputations each year. Between 1/4 to 1/2 of the $ 27.3 billion in direct diabetes in-patient medical expenses is used for the treatment of foot ulcers. There is clearly a si ...

    SBIR Phase II 2003 Department of Health and Human Services
  8. Improved Orthopedic Implant Surface Coatings

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Many contemporary medical and dental therapies include the replacement or repair of tissues using materials such as metal. Currently there are at least 150,000 hip replacements, 300,000 knee replacements, and 500,000 dental implant procedures performed in the US each year (Kurtz, Mowat et al. 2005). These numbers are expected to increase as the baby boom gen ...

    SBIR Phase II 2006 Department of Health and Human Services
  9. Nanoliter Lab-on-a-chip for Protein Crystallization

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): The human genome contains at least 30,000 unique open reading frames that may yield >100,000 polypeptide products. These products assemble into more than a million biologically relevant structures or proteins of interest per organism. Crystallization and X-ray diffraction of these proteins is routinely performed to determine their 3D structure which needs to be ...

    SBIR Phase II 2006 Department of Health and Human Services
  10. Electronic Submission of NIH Grant Applications

    SBC: Clinical Tools, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): This SBIR fast-track application proposes to develop, evaluate, and implement an Internet-based system, called HealthProposal.net to enable electronic grant application preparation and submission. In response to NIH RFA-RR-02-004 (ERA-SBIR) we seek to: 1) provide a state-of-the art web-based interface that enables electronic grant submission, 2) utilize open so ...

    SBIR Phase II 2003 Department of Health and Human Services
US Flag An Official Website of the United States Government